المؤلفون: Zabaleta, Jovanny, Schneider, Barbara G., Ryckman, Kelli, Hooper, Pleasant F., Camargo, M. Constanza, Piazuelo, M. Blanca, Sierra, Rosa A., Fontham, Elizabeth T. H., Correa, Pelayo, Williams, Scott M., Ochoa, Augusto C.

المصدر: Cancer Immunology, Immunotherapy. January 2008 57(1):107-114

المؤلفون: Fontham, Elizabeth T. H., Wolf, Andrew M. D., Church, Timothy R., Etzioni, Ruth, Flowers, Christopher R., Herzig, Abbe, Guerra, Carmen E., Oeffinger, Kevin C., Shih, Ya‐Chen Tina, Walter, Louise C., Kim, Jane J., Andrews, Kimberly S., DeSantis, Carol E., Fedewa, Stacey A., Manassaram‐Baptiste, Deana, Saslow, Debbie, Wender, Richard C., Smith, Robert A., Shih, Ya-Chen Tina, Manassaram-Baptiste, Deana

المصدر: CA: A Cancer Journal for Clinicians; Sep/Oct2020, Vol. 70 Issue 5, p321-346, 26p

مصطلحات موضوعية: EARLY detection of cancer, CERVICAL cancer, CERVICAL intraepithelial neoplasia, CANCER, CYTOLOGY

الشركة/الكيان: AMERICAN Cancer Society Inc., UNITED States. Food & Drug Administration

مستخلص: The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV testing is not available, then individuals aged 25 to 65 years should be screened with cotesting (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years (acceptable) (strong recommendation). The ACS recommends that individuals aged >65 years who have no history of cervical intraepithelial neoplasia grade 2 or more severe disease within the past 25 years, and who have documented adequate negative prior screening in the prior 10 years, discontinue all cervical cancer screening (qualified recommendation). These new screening recommendations differ in 4 important respects compared with the 2012 recommendations: 1) The preferred screening strategy is primary HPV testing every 5 years, with cotesting and cytology alone acceptable where access to US Food and Drug Administration-approved primary HPV testing is not yet available; 2) the recommended age to start screening is 25 years rather than 21 years; 3) primary HPV testing, as well as cotesting or cytology alone when primary testing is not available, is recommended starting at age 25 years rather than age 30 years; and 4) the guideline is transitional, ie, options for screening with cotesting or cytology alone are provided but should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers. Evidence related to other relevant issues was reviewed, and no changes were made to recommendations for screening intervals, age or criteria for screening cessation, screening based on vaccination status, or screening after hysterectomy. Follow-up for individuals who screen positive for HPV and/or cytology should be in accordance with the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. [ABSTRACT FROM AUTHOR]

: Copyright of CA: A Cancer Journal for Clinicians is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Fontham, Elizabeth T. H.

المصدر: CA: A Cancer Journal for Clinicians; Jan/Feb2009, Vol. 59 Issue 1, p5-7, 3p, 1 Color Photograph

مصطلحات موضوعية: CANCER, REGIONAL disparities, OBESITY, TOBACCO, COMMUNICABLE diseases

مصطلحات جغرافية: UNITED States

مستخلص: The author reflects on the mission of the American Cancer Society (ACS) to eliminate cancer as a major health problem in the U.S. She claims that despite the success of the ACS to reduce cancer rates, global disparities in cancer mortality are apparent such as the increase of cancer incidence in low and middle-resource countries. Moreover, she also mentions that the increase of cancer rate is due to tobacco consumption, obesity and continuous threat of cancers caused by infectious disease.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Fontham, Elizabeth T. H., Trapido, Edward

المصدر: Environmental Health Perspectives; Oct2010, Vol. 118 Issue 10, pA422-A423, 2p

مصطلحات موضوعية: ENVIRONMENTAL disasters, EPIDEMIOLOGICAL research, PUBLIC health, CRISIS management, CANCER

مستخلص: The authors reflect on the risk factors of natural disasters to the environment and public health. They highlight the challenges involved in designing and performing optimal epidemiologic studies. They state that cancer and other diseases of long latency from these disasters are taken to reasonable and responsible consideration.